17. №7. 2019

26 ПРАКТИЧЕСКАЯ МЕДИЦИНА
Том 17, № 7. 2019
estimate using health claims data // Neurology. — 2019. — Vol. 92. —
P. e1029–e1040.
2. D’Hooghe M.B., Nagels G., Bissay V., De Keyser J. Modifiable
factors influencing relapses and disability in multiple sclerosis // Mult.
Scler. — 2010. — Vol. 16. — P. 773–785.
3. Houtchens M.K., Edwards N.C., Schneider G., Stern K. et al.
Pregnancy rates and outcomes in women with and without MS in the
United States // Neurology. — 2018. — Vol. 91. — P. e1559–e1569.
4. Comi G., Radaelli M., Soelberg Sørensen P. Evolving concepts
in the treatment of relapsing multiple sclerosis // Lancet. — 2017. —
Vol. 389. — P. 1347–1356.
5. Vaughn C., Bushra A., Kolb C., Weinstock-Guttman B. An
Update on the Use of Disease-Modifying Therapy in Pregnant Patients
with Multiple Sclerosis // CNS Drugs. — 2018. — Vol. 32 (2). —
P. 161–178.
6. Wundes A., Pebdani R.N., Amtmann D. What Do Healthcare
Providers Advise Women with Multiple Sclerosis Regarding
Pregnancy? // Mult Scler Int. — 2014. — P. 1–5.
7. Fragoso Y.D., Adoni T., Brooks J.B.B., Finkelsztejn A. et al.
Practical Evidence-Based Recommendations for Patients with Multiple
Sclerosis Who Want to Have Children // Neurol Ther. — 2018. —
Vol. 7. — P. 207–232.
8. Berenguer-Ruiz L., Gimenez-Martinez J., Palazon-Bru A.,
Sempere A.P. Relapses and obstetric outcomes in women with multiple
sclerosis planning pregnancy // J Neurol. — 2019. doi.org/10.1007/
s00415-019-09450-6
9. Alroughani R., Akhtar S., Zeineddine M., El Kouzi Y. et al. Risk of
relapses during pregnancy among multiple sclerosis patients // Mult
Scler Relat Disord. — 2019. — Vol. 34. — P. 9–13.
10. Sellebjerg F., Barnes D., Filippini G., Midgard R. et al. Acute
relapses of multiple sclerosis / Edited by N.E. Gilhus, M.P. Barnes,
M. Brainin // Chapter 27 in European Handbook of Neurological
Management. — 2011. — Vol. 1, 2 nd Edition.
11. Beck R.W., Cleary P.A. Optic neuritis treatment trial. One-year
follow-up results // Arch Ophthalmol. — 1993. — Vol. 111 (6). —
P. 773–775.
12. Borisow N., Dorr F.P.J. Optimal management of multiple
sclerosis during pregnancy: current perspectives // Degenerative
Neurological and Neuromuscular Disease. — 2014. — Vol. 4. —
P. 111–120.
13. Инструкция по медицинскому применению препарата
Солу-медрол. Одобрена Министерством здравоохранения
РФ 12.08.2009. ЛП-014983/01-200619. Доступно на http://grls.
rosminzdrav.ru
14. Park-Wyllie L., Mazzotta P., Pastuszak A. et al. Birth defects
after maternal exposure to corticosteroids: prospective cohort
study and meta-analysis of epidemiological studies // Teratology. —
2000. — Vol. 62 (6). — P. 385–392.
15. Pradat P., Robert-Gnansia E., Di Tanna G.L., Rosano A. et
al. Contributors to the MADRE database. First trimester exposure
to corticosteroids and oral clefts // Birth Defects Res A Clin Mol
Teratol. — 2003. — Vol. 67. — P. 968–970.
16. Carmichael S.L., Shaw G.M. Maternal corticosteroid use and
risk of selected congenital anomalies // Am J Med Genet. — 1999. —
Vol. 86. — P. 242–244.
17. Rodríguez-Pinilla E., Martinez-Frías M.L. Corticosteroids during
pregnancy and oral clefts: a case-control study // Teratology. —
1998. — Vol. 58. — P. 2–5.
18. Hoes J.N., Jacobs J.W., Boers M., Boumpas D. et al. EULAR
evidence-based recommendations on the management of systemic
glucocorticoid therapy in rheumatic diseases // Ann Rheum Dis. —
2007. — Vol. 66. — P. 1560–1567.
19. Namazy J.A., Murphy V.E., Powell H., Gibson P.G. et al.
Effects of asthma severity, exacerbations and oral corticosteroids on
perinatal outcomes // Eur Respir J. — 2013. Vol. 41. — P. 1082–1090.
20. Elliott A.B., Chakravarty E.F. Immunosuppressive medications
during pregnancy and lactation in women with autoimmune diseases //
Womens Health (Lond Engl). — 2010. — Vol. 6. — P. 431–440.
21. Hellwig K. Pregnancy in multiple sclerosis // Eur Neurol. —
2014. — Vol. 72, Suppl 1. — P. 39–42.
22. Gur C., Diav-Citrin O., Shechtman S., Arnon J. et al.
Pregnancy outcome after first trimester exposure to corticosteroids:
a prospective controlled study // Reprod Toxicol. — 2004. —
Vol. 18 (1). — P. 93–101.
23. Ferrero S., Pretta S., Ragni N. Multiple sclerosis: management
issues during pregnancy // Eur J Obstet Gynecol Reprod Biol. —
2004. — Vol. 115 (1). — P. 3–9.
24. Dobson R., Dassan P., Roberts M. et al. UK consensus on
pregnancy in multiple sclerosis: ‘Association of British Neurologists’
guidelines // Pract Neurol. — 2019. — Vol. 19. — P. 106–114
25. Argyriou A.A., Makris N. Multiple sclerosis and reproductive
risks in women // Reprod Sci. — 2008. — Vol. 15 (8). — P. 755–764.
26. Voskuhl R., Momtazee C. Pregnancy: Effect on multiple
sclerosis, treatment considerations and breastfeeding // Neurother. —
2017. — Vol. 14. — P. 974–984.
27. Cooper S.D., Felkins K., Baker T.E., Hale T.W. Transfer of methyl
prednisolone into breast milk in a mother with multiple sclerosis // J
Hum Lact. — 2015. — Vol. 31 (2). — P. 237–239.
28. Wesselink A.K., Rothman K.J., Hatch E.E., Mikkelsen E.M.
et al. Age and fecundability in a North American preconception cohort
study // Am J Obstet Gynecol. — 2017. — Vol. 217 (6). — P. 667,
e661–667, e668. doi: 10.1016/j.ajog.2017.09.002
29. Alroughani R., Alowayesh M.S., Ahmed S.F., Behbehani R.,
Al-Hashel J. Relapse occurrence in women with multiple sclerosis
during pregnancy in the new treatment era // Neurology. — 2018. —
Vol. 90 (10). — P. e840–e846.
30. Coyle P.K. Management of women with multiple sclerosis
through pregnancy and after childbirth // Ther Adv Neurol Disord. —
2016. — Vol. 9 (3). — P. 198–210.
31. Portaccio E., Moiola L., Martinelli V. et al. Pregnancy decisionmaking
in women with multiple sclerosis treated with natalizumab:
II: Maternal risks // Neurology. — 2018. — Vol. 90. — P. e832–e839.
32. Bove R., Alwan S., Friedman J.M., Hellwig K et al. Management
of multiple sclerosis during pregnancy and the reproductive years:
a systematic review // Obstet Gynecol. — 2014. — Vol. 124 (6). —
P. 1157–1168.
33. Sandberg-Wollheim M., Neudorfer O., Grinspan A., Weinstock-
Guttman B. et al. Pregnancy outcomes from the branded glatiramer
acetate pregnancy database // Int J MS Care. — 2018. — Vol. 20. —
P. 9–14.
34. Friend S., Richman S., Bloomgren G., Cristiano L.M., Wenten
M. Evaluation of pregnancy outcomes from the Tysabri (natalizumab)
pregnancy exposure registry: a global, observational, follow-up
study // BMC Neurol. — 2016. — Vol. 16. — P. 150.
35. Hellwig K., Geissbuehler Y., Sabido M., Popescu C. et al.
Pregnancy and infant outcomes with interferon beta: data from the
European interferon beta pregnancy registry and population based
registries in Finland and Sweden. Presented at ECTRIMS 2018; 10-
12 October; Berlin, Germany. Abstract No. A-0950-0000-02658.
Доступно на https://www.merckneurology.com/content/dam/web/
healthcare/biopharma/neurology/merckneurology/images/Extrims/
docs/Abstract-19-Hellwig-et-al.ECTRIMS-2018-P1753.pdf Last access
on 15.09.19
36. Houtchens M. Multiple sclerosis and pregnancy // Clin Obstet
Gynecol. — 2013. — Vol. 56 (2). — P. 342–349.
37. Herbstritt S., Langer-Gould A., Rockhoff M., Haghikia A. et
al. Glatiramer acetate during early pregnancy: a prospective cohort
study // Mult Scler. — 2016. — Vol. 22. — P. 810–816.
38. Giannini M., Portaccio E., Ghezzi A., Hakiki B. et al. Pregnancy
and fetal outcomes after Glatiramer Acetate exposure in patients with
multiple sclerosis: a prospective observational multicentric study //
BMC Neurol. — 2012. — Vol. 12. — P. 124.
39. Amato M.P., Portaccio E., Ghezzi A., Hakiki B. et al. Pregnancy
and fetal outcomes after interferon-beta exposure in multiple
sclerosis // Neurology. — 2010. — Vol. 75 (20). — P. 1794–1802.
40. Sandberg-Wollheim M., Alteri E., Moraga M.S., Kornmann G.
Pregnancy outcomes in multiple sclerosis following subcutaneous
interferon beta-1a therapy // Mult Scler. — 2011. — Vol. 17 (4). —
P. 423–430.
41. Lu E., Wang B.W., Guimond C., Synnes A. et al. Diseasemodifying
drugs for multiple sclerosis in pregnancy: a systematic
review // Neurology. — 2012. — Vol. 79 (11). — P. 1130–1135.
42. Hellwig K., Haghikia A., Rockhoff M., Gold R. Multiple sclerosis
and pregnancy: experience from a nationwide database in Germany //
Ther Adv Neurol Disord. — 2012. — Vol. 5 (5). — P. 247–253.
43. Fragoso Y.D., Boggild M., Macias-Islas M.A., Carra A. et al.
The effects of long-term exposure to disease-modifying drugs during
pregnancy in multiple sclerosis // Clin Neurol Neurosurg. — 2013. —
Vol. 115 (2). — P. 154–159.
44. Weber-Schoendorfer C., Schaefer C. Multiple sclerosis,
immunomodulators, and pregnancy outcome: a prospective
observational study // Mult Scler. — 2009. — Vol. 15 (9). —
P. 1037–1042.
45. Fragoso Y.D., Finkelsztejn A., Comini-Frota E.R., da Gama P.D.,
Grzesiuk A.K., Khouri J.M. et al. Pregnancy and multiple sclerosis:
the initial results from a Brazilian database // Arq Neuropsiquiatr. —
2009. — Vol. 67 (3A). — P. 657–660.
46. Hellwig K., Haghikia A., Gold R. Parenthood and
immunomodulation in patients with multiple sclerosis // J Neurol. —
2010. — Vol. 257 (4). — P. 580–583.
47. Coyle P.K., Sinclair S.M., Scheuerle A.E., Thorp J.M. et al. Final
results from the Betaseron (interferon b-1b) pregnancy registry: a
prospective observational study of birth defects and pregnancyrelated
adverse events // BMJ Open. — 2014. — Vol. 4. — P. e004536.
48. Thiel S., Langer-Gould A., Rockhoff M., Haghikia A. et al.
Interferon-beta exposure during first trimester is safe in women with
multiple sclerosis — a prospective cohort study from the German
Multiple Sclerosis and Pregnancy Registry // Mult Scler. — 2016. —
Vol. 22. — P. 801–809.
49. Alroughani R., Altintas A., Al Jumah M., Sahraian M.,
Alsharoqi I., AlTahan A. et al. Pregnancy and the use of diseasemodifying
therapies in patients with multiple sclerosis: benefits versus
risks // Mult Scler Int. — 2016; 2016:1034912.
50. Davenport L., Czich A., Turpault S. Teriflunomide: non-clinical
evaluation demonstrates no effect on sperm DNA or male fertility
[abstract] // Neurology. — 2014. — Vol. 82 (10 Suppl). — P. 233.